M Colombié1, L Campion2,3, C Bailly4, D Rusu4, T Rousseau5, C Mathieu6, L Ferrer7, N Rousseau4, F Kraeber-Bodéré4,6,3, C Rousseau4,3. 1. Nuclear Medicine, Institut de Cancérologie de l'Ouest René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France. mathilde.colombie@ico.unicancer.fr. 2. Statistics, ICO Cancer Center, Saint-Herblain, France. 3. Nantes-Angers Cancer Research Center, INSERM U892-CNRS UMR 6299, Nantes University, Nantes, France. 4. Nuclear Medicine, Institut de Cancérologie de l'Ouest René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France. 5. Urologic Clinic Nantes-Atlantis, Saint Herblain, France. 6. Nuclear Medicine, University Hospital, Nantes, France. 7. Physics, ICO Cancer Center, Saint-Herblain, France.
Abstract
PURPOSE: To evaluate the therapeutic impact of (18)F-fluorocholine (FCH) PET/CT in biochemical recurrent prostate cancer (PC) and to investigate the value of quantitative FCH PET/CT parameters in predicting progression-free survival (PFS). METHODS: This retrospective study included 172 consecutive patients with PC who underwent FCH PET/CT for biochemical recurrence. Mean rising PSA was 10.7 ± 35.0 ng/ml. Patients with positive FCH PET were classified into three groups: those with uptake only in the prostatic bed, those with locoregional disease, and those with distant metastases. Referring physicians were asked to indicate the hypothetical therapeutic strategy with and without the FCH PET/CT results. Clinical variables and PET parameters including SUVmax, SUVpeak, SUVmean, total lesion choline kinase activity (TLCKA) and standardized added metabolic activity (SAM) were recorded and a multivariate analysis was performed to determine the factors independently predicting PFS. RESULTS: In 137 of the 172 patients, the FCH PET/CT scan was positive, and of these, 29.9 % (41/137) had prostatic recurrence, 42.3 % (58/137) had pelvic lymph node recurrence with or without prostatic recurrence, and 27.7 % (38/137) had distant metastases. The FCH PET/CT result led to a change in treatment plan in 43.6 % (75/172) of the 172 patients. Treatment was changed in 49.6 % (68/137) of those with a positive FCH PET/CT scan and in 20 % (7/35) of those with a negative FCH PET/CT scan. After a median follow-up of 29.3 months (95 % CI 18.9 - 45.9 months), according to multivariate analysis age <70 years, SAM ≥23 and SUVmean ≥3 were parameters independently predicting PFS. A nomogram constructed using the three parameters showed 49 months of PFS in patients with the best scores (0 or 1) and only 11 months in patients with a poor score (score 3). CONCLUSION: This study indicates that a positive FCH PET result in PC patients with biochemical recurrence predicts a shorter PFS and confirms the major impact of the FCH PET result on the management of biochemical recurrent PC.
PURPOSE: To evaluate the therapeutic impact of (18)F-fluorocholine (FCH) PET/CT in biochemical recurrent prostate cancer (PC) and to investigate the value of quantitative FCH PET/CT parameters in predicting progression-free survival (PFS). METHODS: This retrospective study included 172 consecutive patients with PC who underwent FCH PET/CT for biochemical recurrence. Mean rising PSA was 10.7 ± 35.0 ng/ml. Patients with positive FCH PET were classified into three groups: those with uptake only in the prostatic bed, those with locoregional disease, and those with distant metastases. Referring physicians were asked to indicate the hypothetical therapeutic strategy with and without the FCH PET/CT results. Clinical variables and PET parameters including SUVmax, SUVpeak, SUVmean, total lesion choline kinase activity (TLCKA) and standardized added metabolic activity (SAM) were recorded and a multivariate analysis was performed to determine the factors independently predicting PFS. RESULTS: In 137 of the 172 patients, the FCH PET/CT scan was positive, and of these, 29.9 % (41/137) had prostatic recurrence, 42.3 % (58/137) had pelvic lymph node recurrence with or without prostatic recurrence, and 27.7 % (38/137) had distant metastases. The FCH PET/CT result led to a change in treatment plan in 43.6 % (75/172) of the 172 patients. Treatment was changed in 49.6 % (68/137) of those with a positive FCH PET/CT scan and in 20 % (7/35) of those with a negative FCH PET/CT scan. After a median follow-up of 29.3 months (95 % CI 18.9 - 45.9 months), according to multivariate analysis age <70 years, SAM ≥23 and SUVmean ≥3 were parameters independently predicting PFS. A nomogram constructed using the three parameters showed 49 months of PFS in patients with the best scores (0 or 1) and only 11 months in patients with a poor score (score 3). CONCLUSION: This study indicates that a positive FCH PET result in PC patients with biochemical recurrence predicts a shorter PFS and confirms the major impact of the FCH PET result on the management of biochemical recurrent PC.
Entities:
Keywords:
18F-Choline; Biochemical recurrence; Metabolic parameters; PET/CT; Prostate cancer
Authors: Giampiero Giovacchini; Maria Picchio; Rita Garcia-Parra; Alberto Briganti; Firas Abdollah; Luigi Gianolli; Christian Schindler; Francesco Montorsi; Cristina Messa; Ferruccio Fazio Journal: J Nucl Med Date: 2014-01-09 Impact factor: 10.057
Authors: Vera Graute; Nathalie Jansen; Christopher Ubleis; Michael Seitz; Markus Hartenbach; Michael Karl Scherr; Sven Thieme; Paul Cumming; Katharina Klanke; Reinhold Tiling; Peter Bartenstein; Marcus Hacker Journal: Eur J Nucl Med Mol Imaging Date: 2011-11-16 Impact factor: 9.236
Authors: Daniel T Schmid; Hubert John; Roland Zweifel; Tibor Cservenyak; Gerrit Westera; Gerhard W Goerres; Gustav K von Schulthess; Thomas F Hany Journal: Radiology Date: 2005-05 Impact factor: 11.105
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: Sanoj Punnen; Matthew R Cooperberg; Anthony V D'Amico; Pierre I Karakiewicz; Judd W Moul; Howard I Scher; Thorsten Schlomm; Stephen J Freedland Journal: Eur Urol Date: 2013-05-16 Impact factor: 20.096
Authors: Christopher J Kane; Christopher L Amling; Peter A S Johnstone; Nali Pak; Raymond S Lance; J Brantley Thrasher; John P Foley; Robert H Riffenburgh; Judd W Moul Journal: Urology Date: 2003-03 Impact factor: 2.649
Authors: Daniela E Oprea-Lager; Andrew D Vincent; Reindert J A van Moorselaar; Winald R Gerritsen; Alfons J M van den Eertwegh; Jonas Eriksson; Ronald Boellaard; Otto S Hoekstra Journal: PLoS One Date: 2012-10-31 Impact factor: 3.240
Authors: Anthony Turpin; Edwina Girard; Clio Baillet; David Pasquier; Jonathan Olivier; Arnauld Villers; Philippe Puech; Nicolas Penel Journal: Front Oncol Date: 2020-01-31 Impact factor: 6.244